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0.001). For every 6 patients switching in cohort 1, 10 patients
switched in cohort 2 (hazard ratio: 0.62, 95% CI: 0.57–0.69).
The introduction of generic omeprazole resulted in decreasing
expenditures for omeprazole (−€140 million; −56%) and for all
PPIs (−€52 million; −16%) between 2001–2004. However, some
savings have been missed due to increased switching from the
generic product. Further results will be presented on statins of
which analyses are currently conducted. CONCLUSIONS: After
patent expiry, more patients switch from omeprazole to another
PPI. It is however debatable whether a 5% increase in ‘switch-
ers’ is relevant in the light of enormous decreased expenditures
due to generic substitution.
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OBJECTIVES: To determine the demands on health care
resources caused by disease, age and gender and to demonstrate
the importance of the perspective on health expenditure
(national versus international). METHODS: A generic top-down
cost-of-illness analysis was performed for The Netherlands.
Expenditure per provider in 2003 was known for three perspec-
tives on health care costs: the OECD’s System of Health
Accounts (SHA) and two national perspectives. Data on health
care use were collected from 70 registries of which the most
important had national coverage. These were mapped on expen-
diture to estimate cost of illness and enabled analysis in six
dimensions: provider, health care function, source of funding,
age, gender and disease. Outcome measures were total costs and
costs per capita. RESULTS: Mental diseases represent the most
expensive main diagnostic group (22% of total costs). Heart dis-
eases come second (9.2%). Neoplasms come on a 7th place
(4.1%). The three perspectives showed minor differences in
ranking of disease groups. Total costs differed widely between
perspectives: €43.7 to €57.5 billion (9–12% GDP), the higher
estimate based on the perspective of the Dutch National Health
Accounts, the lower on the perspective of the Dutch ministry of
Health. The international SHA-perspective came close in total
costs to the ministry of Health estimate (€45.1 billion), but had
a radical different composition. Cost increase by age, sharply
from 65+ onwards until €50,000 per citizen for the oldest old.
In the SHA-approach the increase is less steep because of the
exclusion of speciﬁc health provisions for Dutch elderly. CON-
CLUSIONS: The perspective on health expenditure has an
important inﬂuence on coi-estimates, especially for per capita
costs and to a lesser extent for the relative expenditure on par-
ticular diseases. Insight in the differences between perspectives
enables better national and international comparisons between
coi-studies.
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Current clinical data show that every third hospitalized patient
in Germany is malnourished. This indicates a need for manda-
tory nutrition status screening and evidence based clinical nutri-
tion. The cost-effectiveness-estimate of this concept has not yet
been evaluated by a diagnosis based severity-of-disease risk-
adjustment. NUTRICORE is the ﬁrst study worldwide, using the
predictive scale of Disease Staging to get valid data on risk-
adjusted clinical and economic outcomes in the ﬁeld of clinical
nutrition research on large patient populations (>10,000).
OBJECTIVES: To show a positive correlation of an evidence
based clinical nutrition concept on clinical and economic out-
comes in malnourished hospitalized patients by risk-adjustment
on severity of disease and corresponding cost-effectiveness-
analysis. METHODS: NUTRICORE SP1 is a prospective con-
trolled interventional multicenter based clinical trial with more
than 10,000 patients from German Hospitals. The nutrition
status of each patient is screened and combined with clinical
data, utilization data and direct costs on the basis of clinical
homogenous patient clusters. The risk adjustment scales can be
run by routine data sets from German inpatient G-DRG system
2006. In the control period starting in June 2006 the effects of
usual nutrition care are documented. Starting the intervention
period in October 2006 an implementation of an interdiscipli-
nary evidence-based guideline for screening and clinical nutrition
will be introduced in each participating hospital. RESULTS:
NUTRICORE SP1 has been piloted in two 600-bed-hospitals in
Germany during 2005, showing a signiﬁcant reduction of costs
for clinical nutrition by €152,544.00 per year for a risk-adjusted
patient population of €38,004 cases in total. CONCLUSIONS:
The study NUTRICORE SP1 is intended to show signiﬁcant clin-
ical improvements and signiﬁcant cost-effectiveness by the imple-
mentation of an evidence based nutrition concept within clinical
homogenous patient groups leading to reduction of Length of
Stay (LOS), Inpatient Mortality, Complications-of-Care, hospi-
tal readmission.
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OBJECTIVES: To analyze the evolution of the pharmaceutical
public expenditure and to evaluate the impact of supply mea-
sures of restraint over its growth. METHODS: Time series analy-
sis through linear autoregressive multivariate models (January
1999–June 2005). Source: monthly pharmaceutical invoices.
Dependent variables: total public expenditure (E), number of
prescriptions adjusted by days (P/d), and average public expen-
diture per prescription (E/P). Independent variables analyzed:
trend, seasonal variation, cycles, number of days and lags when
necessary. Impacts analyzed: introduction of maximum margins
for wholesalers and chemists’ and discounts over chemists’
turnovers (D), and introduction of two reference pricing groups
(RPG1 & RPG2 respectively). Lags are also introduced when
residual autocorrelation occurs. Models are validated through
normal contrast and no-correlation of residual. RESULTS:
Adjusted R2 are 0.818, 0.684 and 0.814 in E, P/d and E/P when
trend is considered as unique variable. There are no seasonal
variation at any time series (p > 0.1) when this variable is related
to four seasons as a categorical variable. However, August has
been entered in E and P/d models as a dichotomic variable (p <
0.0001 & p < 0.01). Number of days also entered in E model 
(p < 0.0001). Annual cycle is observed in P/d and E/P model 
(p < 0.05) and half-yearly and cuatrimestral cycles also entered
in P/d model (p < 0.05). Two supply measures present impacts
at the short term. D has entered in the three models: E (p < 0.001;
Beta: −8,733,966), P/d (Beta: −13,100) and E/P (Beta: −0.18) 
(p < 0.05 both). RPG2 has been also considered in E (Beta: 
